Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM)

被引：0
|
作者：
Richardson, Paul [1 ]
Hofmeister, Craig [2 ]
Jakubowiak, Andrzej [3 ]
Zimmerman, Todd M. [5 ]
Spear, Matthew A. [4 ]
Palladino, Michael A. [4 ]
Longenecker, Angie M. [4 ]
Kelly, Susan L. [6 ]
Neuteboom, Saskia [7 ]
Cropp, Gillian F. [4 ]
Lloyd, G. Kenneth [4 ]
Hannah, Alison L. [4 ]
Anderson, Kenneth C. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Ohio State Univ, Med Ctr, Div Hematol, Columbus, OH 43210 USA
[3] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[4] Nereus Pharmaceut Inc, San Diego, CA USA
[5] Univ Chicago, Chicago, IL 60637 USA
[6] Multiple Myeloma Res Fdn, Norwalk, CT USA
[7] Nereus Pharmaceut Inc, San Diego, CA USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：179 / 179
页数：1
相关论文
共 50 条
  • [41] Combined autophagy and proteasome inhibition A phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma
    Vogl, Dan T.
    Stadtmauer, Edward A.
    Tan, Kay See
    Heitjan, Daniel F.
    Davis, Lisa E.
    Pontiggia, Laura
    Rangwala, Reshma
    Piao, Shengfu
    Chang, Yunyoung C.
    Scott, Emma C.
    Paul, Thomas M.
    Nichols, Charles W.
    Porter, David L.
    Kaplan, Janeen
    Mallon, Gayle
    Bradner, James E.
    Amaravadi, Ravi K.
    AUTOPHAGY, 2014, 10 (08) : 1380 - 1390
  • [42] CARDIAC STRUCTURE AND FUNCTION IN PATIENTS TREATED WITH PROTEASOME INHIBITORS FOR RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
    Dahm, Cherie
    Mallugari, Ravinder
    Ky, Bonnie
    Cornell, Robert
    Lenihan, Daniel
    Gupta, Deepak K.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 1085 - 1085
  • [43] Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma
    Vogl, Dan T.
    Martin, Thomas G.
    Vij, Ravi
    Hari, Parameswaran
    Mikhael, Joseph R.
    Siegel, David
    Wu, Ka Lung
    Delforge, Michel
    Gasparetto, Cristina
    LEUKEMIA & LYMPHOMA, 2017, 58 (08) : 1872 - 1879
  • [44] Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
    S K Kumar
    B LaPlant
    V Roy
    C B Reeder
    M Q Lacy
    M A Gertz
    K Laumann
    M A Thompson
    T E Witzig
    F K Buadi
    C E Rivera
    J R Mikhael
    P L Bergsagel
    P Kapoor
    L Hwa
    R Fonseca
    A K Stewart
    A Chanan-Khan
    S V Rajkumar
    A Dispenzieri
    Blood Cancer Journal, 2015, 5 : e338 - e338
  • [45] Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
    Kumar, S. K.
    LaPlant, B.
    Roy, V.
    Reeder, C. B.
    Lacy, M. Q.
    Gertz, M. A.
    Laumann, K.
    Thompson, M. A.
    Witzig, T. E.
    Buadi, F. K.
    Rivera, C. E.
    Mikhael, J. R.
    Bergsagel, P. L.
    Kapoor, P.
    Hwa, L.
    Fonseca, R.
    Stewart, A. K.
    Chanan-Khan, A.
    Rajkumar, S. V.
    Dispenzieri, A.
    BLOOD CANCER JOURNAL, 2015, 5 : e338 - e338
  • [46] Requirement of caspase-8 versus caspase-9 during apoptosis in multiple myeloma cells induced by Bortezomib -: Or a novel proteasome inhibitor NPI-0052
    Chauhan, D
    Catley, L
    Velankar, M
    Letai, A
    Hideshima, T
    Podar, K
    Yasui, H
    Mitsiades, N
    Mitsiades, C
    Tai, YT
    Raje, N
    Munshi, N
    Palladino, MA
    Anderson, KC
    BLOOD, 2005, 106 (11) : 944A - 944A
  • [47] Bortezomib in patients with relapsed-refractory multiple myeloma (MM). Clinical observations.
    Kyrtsonis, MC
    Sachanas, S
    Vassilakopoulos, TP
    Kafassi, N
    Tzenou, T
    Papadogiannis, A
    Kalpadakis, C
    Antoniadis, AG
    Dimopoulou, MN
    Angelopoulou, MK
    Siakantaris, MP
    Dimitriadou, EM
    Kokoris, SI
    Plata, E
    Tsaftaridis, P
    Panayiotidis, P
    Pangalis, GA
    BLOOD, 2005, 106 (11) : 382B - 382B
  • [48] Update on phase I clinical trial of IPI-504, a novel, water-soluble Hsp90 inhibitor, in patients with relapsed/refractory multiple myeloma (MM).
    Siegel, David
    Jagannath, Sundar
    Mazumder, Amitabha
    Vesole, David
    Borrello, Ivan
    Sydor, Jens
    Wright, Jim
    Patterson, Jon
    Normant, Emmanuel
    Adams, Julian
    Anderson, Kenneth
    Grayzel, David
    Richardson, Paul
    BLOOD, 2006, 108 (11) : 1022A - 1022A
  • [49] A Phase 1 Study of Tasquinimod in Patients with Relapsed or Refractory Multiple Myeloma
    Vogl, Dan T.
    Nefedova, Yulia
    Wileyto, E. Paul
    Sembhi, Harjeet
    Strakovsky, Inna
    Nguyen, Chau
    Taneja, Rimzim
    Bondesson, Eva
    Eriksson, Helena
    Tuvesson, Helen
    BLOOD, 2020, 136
  • [50] The ICARIA-MM trial: a new standard of treatment for relapsed or refractory multiple myeloma with lenalidomide and proteasome inhibitors?
    Levy, Anthony
    Leleu, Xavier
    Moya, Niels
    HEMATOLOGIE, 2020, 26 (01): : 7 - 8
12345